0HF3.L
Cencora
Q3 2025 Report
Cencora (0HF3.L) Q3 2025 Financial Results: Robust Growth Amidst Industry Challenges...
Read full report
Executive Summary
Cencora (0HF3.L) showcased a robust performance in Q3 2024, achieving revenue of $74.24 billion, reflecting an 8.52% increase quarter-over-quarter (QoQ) and 7.72% year-over-year (YoY). Despite challenges in gross profit driven by higher costs, the company demonstrated an impressive 37.91% surge in net income, amounting to $483.46 million, supported by effective cost management and strategic market positioning. Management emphasized their commitment to expanding operations in both domestic and international pharmaceutical distribution, enhancing service capabilities, which positions them well against competitive pressures in the industry.
Key Performance Indicators
Revenue
74.24B
QoQ: 8.52% | YoY:7.72%
Gross Profit
2.09B
2.81% margin
QoQ: -7.93% | YoY:-5.62%
Operating Income
703.37M
QoQ: -19.84% | YoY:30.07%
Net Income
483.46M
QoQ: 14.90% | YoY:37.91%
EPS
2.44
QoQ: 15.64% | YoY:41.04%
Revenue Trend
Margin Analysis
Key Insights
Revenue: $74.24 billion, YoY Growth: 7.72%, QoQ Growth: 8.52%. Gross Profit: $2.09 billion, YoY Decline: 5.62%, QoQ Decline: 7.93%. Operating Income: $703.37 million, YoY Growth: 30.07%, QoQ Decline: 19.84%. Net Income: $483.46 million, YoY Growth: 37.91%, QoQ Growth: 14.90%. EPS: $2.44, YoY Growth: 41.04%, QoQ Growth: 15.64%. These shifts indicate a strong bottom line performance despite increased operational challenges and highlight management's effective cost controls amid fluctuating ...